Tumor-derived inflammatory cytokine signaling

Tumor-derived inflammatory cytokine signaling encompasses the secretion of various cytokines by tumor and stromal cells within the tumor microenvironment, including interleukins (e.g., IL-6, IL-1β), tumor necrosis factor-alpha (TNF-α), interferons (IFNs), and transforming growth factor-beta (TGF-β)[1][3][5]. These cytokines function via autocrine and paracrine mechanisms through their respective receptors to activate intracellular pathways such as JAK-STAT, NF-κB, and MAPK, leading to promotion of tumor growth, immune evasion, angiogenesis, metastasis, and drug resistance. Therapeutic strategies target individual cytokine signaling pathways rather than this highly generalized process as a singular druggable target[1][3][5][7][9]. This entry is **not a specific molecular target** but describes a process; the term is too broad for canonical drug target cataloging. If structured annotation of real targets involved is desired, reference canonical cytokine receptors (e.g., “Interleukin-6 receptor,” “Tumor necrosis factor receptor 1”) or downstream effectors (e.g., “Janus kinase 1,” “STAT3”).

Other names

Tumor inflammatory cytokine signalingTumor cytokine signalingTumor-associated cytokine pathwaysInflammatory cytokine signaling in TME

Mechanisms depend on the specific cytokine/receptor targeted, e.g., cytokine-neutralization, receptor antagonism, JAK-STAT inhibition.